Canadian Technology Stocks
BufferThis past Wednesday DiagnoCure (TSX:CUR), along with its US-based partner Gen-Probe, received FDA approval for its lead prostate cancer diagnostic biomarker PCA3, which will be branded as Progensa. Byron Capital Healthcare and Biotech analyst Douglas Loe says this news signals a new era in Diagnocure’s history. In a research update last week, Loe upgraded Diagnocure [...]
BufferLast Thursday, YM Biosciences (TSX:YM) reported its Q2, 2012 results. The company lost $6.55-million on revenues of just under $400K. The Mississauga based biotech’s scant revenue has declined each year since 2007, when it posted a $7.6 million topline. But Byron Capital Healthcare analyst Douglas Loe says pay no attention to today’s financial results, and [...]
BufferA cursory glance at a three-year chart of Belleville’s Bioniche Life Sciences (TSX:BNC) illustrates the promise and subsequent disappointment of the company’s plans to expand beyond its core business. A closer look reveals a minor resurgence is underway, as the company has focused on the bottom line during the transition. For years, Bioniche was better [...]
Buffer2008 was supposed to be Medipattern’s (TSXV:MKI) big year. The Toronto based company, which designs medical imaging software, went public in 2005, then soared to $1.64 in the first days of 2008 on the promise of a new medical imaging system for breast cancer detection. When the tangle of regulatory hurdles combined with the worst [...]
BufferShares of CardioComm (TSXV:EKG) were on fire today after the company announced it had cleared an important hurdle in its goal to market a new handheld ECG device called the HeartCheck Pen. CardioComm received confirmation from the Canadian Medical Devices Conformity Assessment System that it had cleared an ISO (International Organization for Standardization) audit performed [...]
BufferIf you want telecom you go to Ottawa. If you want oil and gas technology, go to Alberta. When it comes to biotech, Quebec is Canada’s undisputed champion. Quebec ranks fourth in North America in terms of the number of biotech firms, and all of the world’s top ten pharmaceutical companies all have operations there. [...]
BufferNeptune Technologies (TSXV:NTB) yesterday reported its Q3, 2012 results. The numbers appeared to be a mixed bag; revenue was up by 19% to $5.12 million, but the company wasn’t able to reverse a history of losses, tacking on another $1.43 million to the downside. Byron Capital healthcare and biotechnology analyst Douglas Loe, however, says he [...]
BufferThe long and winding road. Investors know progress in biotech can be painfully slow. Oncolytics Biotech (TSX:ONC) can trace its history all the way back to the early 1990′s and discoveries made in the Department of Microbiology and Infectious Diseases at the University of Calgary. The company has since poured ten of millions of dollars [...]
BufferCAE Inc. (TSX:CAE), which was founded in 1947 in Saint-Hubert, Quebec has built a billion dollar business on the back of flight simulators. The company is the gold standard in the industry, having sold their simulators to over a hundred different airlines. The company now trains more than 75,000 crew members each year, many at [...]
BufferIn a recent note to clients, Byron Capital’s Healthcare and Biotech Analyst Douglas Loe reiterated his Speculative Buy target on Protox Therapeutics (TSX:PRX), whose stock has been on a slide since May, from over $.70 cents to 2011′s close of $.33 cents. Loe’s target for the Vancouver based biopharm is $1. Loe believes the market [...]
